Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1883–1886. doi: 10.1054/bjoc.2001.2185

Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies

C Moch 1, A Moysan 1, R Lubin 2, P de La Salmonière 3, N Soufir 1, F Galisson 1, C Vilmer 1, E Venutolo 1, F Le Pelletier 4, A Janin 4, N Basset-Séguin 1
PMCID: PMC2364020  PMID: 11747330

Abstract

Circulating anti-p53 antibodies have been described and used as tumoural markers in patients with various cancers and strongly correlate with the p53 mutated status of the tumours. No study has yet looked at the prevalence of such antibodies in skin carcinoma patients although these tumours have been shown to be frequently p53 mutated. Most skin carcinoma can be diagnosed by examination or biopsy, but aggressive, recurrent and/or non-surgical cases' follow up would be helped by a biological marker of residual disease. We performed a prospective study looking at the prevalence of anti-p53 antibodies using an ELISA technique in a series of 105 skin carcinoma patients in comparison with a sex- and age-matched control skin carcinoma-free group (n = 130). Additionally, p53 accumulation was studied by immunohistochemistry to confirm p53 protein altered expression in a sample of tumours. Anti-p53 antibodies were detected in 2.9% of the cases, with a higher prevalence in patients suffering from the more aggressive squamous cell type (SCC) of skin carcinoma (8%) than for the more common and slowly growing basal cell carcinoma type or BCC (1.5%). p53 protein stabilization could be confirmed in 80% of tumours studied by IHC. This low level of anti-p53 antibody detection contrasts with the high rate of p53 mutations reported in these tumours. This observation shows that the anti-p53 humoral response is a complex and tissue-specific mechanism. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: skin tumours, basal cell carcinomas, squamous cell carcinoma, anti-p53 antibodies, tumoural markers

Full Text

The Full Text of this article is available as a PDF (48.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  2. Basset-Séguin N., Molès J. P., Mils V., Dereure O., Guilhou J. J. TP53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol. 1994 Nov;103(5 Suppl):102S–106S. doi: 10.1111/1523-1747.ep12399372. [DOI] [PubMed] [Google Scholar]
  3. Beissert S., Schwarz T. Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc. 1999 Sep;4(1):61–64. doi: 10.1038/sj.jidsp.5640183. [DOI] [PubMed] [Google Scholar]
  4. Bourhis J., Lubin R., Roche B., Koscielny S., Bosq J., Dubois I., Talbot M., Marandas P., Schwaab G., Wibault P. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Sep 4;88(17):1228–1233. doi: 10.1093/jnci/88.17.1228. [DOI] [PubMed] [Google Scholar]
  5. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  6. Firestein G. S., Nguyen K., Aupperle K. R., Yeo M., Boyle D. L., Zvaifler N. J. Apoptosis in rheumatoid arthritis: p53 overexpression in rheumatoid arthritis synovium. Am J Pathol. 1996 Dec;149(6):2143–2151. [PMC free article] [PubMed] [Google Scholar]
  7. Hammel P., Boissier B., Chaumette M. T., Piedbois P., Rotman N., Kouyoumdjian J. C., Lubin R., Delchier J. C., Soussi T. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut. 1997 Mar;40(3):356–361. doi: 10.1136/gut.40.3.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hammel P., Leroy-Viard K., Chaumette M. T., Villaudy J., Falzone M. C., Rouillard D., Hamelin R., Boissier B., Remvikos Y. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer. 1999 May 31;81(5):712–718. doi: 10.1002/(sici)1097-0215(19990531)81:5<712::aid-ijc7>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  9. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
  10. Kaur J., Srivastava A., Ralhan R. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer. 1997 Dec 19;74(6):609–613. doi: 10.1002/(sici)1097-0215(19971219)74:6<609::aid-ijc9>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  11. Lubin R., Zalcman G., Bouchet L., Trédanel J., Legros Y., Cazals D., Hirsch A., Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995 Jul;1(7):701–702. doi: 10.1038/nm0795-701. [DOI] [PubMed] [Google Scholar]
  12. Peyrat J. P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995 Mar 11;345(8950):621–622. doi: 10.1016/s0140-6736(95)90523-5. [DOI] [PubMed] [Google Scholar]
  13. Rainov N. G., Dobberstein K. U., Fittkau M., Bahn H., Holzhausen H. J., Gantchev L., Burkert W. Absence of p53 autoantibodies in sera from glioma patients. Clin Cancer Res. 1995 Jul;1(7):775–781. [PubMed] [Google Scholar]
  14. Ren Z. P., Hedrum A., Pontén F., Nistér M., Ahmadian A., Lundeberg J., Uhlén M., Pontén J. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene. 1996 Feb 15;12(4):765–773. [PubMed] [Google Scholar]
  15. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992 Nov 15;52(22):6380–6384. [PubMed] [Google Scholar]
  16. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000 Apr 1;60(7):1777–1788. [PubMed] [Google Scholar]
  17. Zalcman G., Schlichtholz B., Trédaniel J., Urban T., Lubin R., Dubois I., Milleron B., Hirsch A., Soussi T. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Cancer Res. 1998 Jun;4(6):1359–1366. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES